S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
PARP inhibitors: OlympiAD and EMBRACA impact
Heather McArthur summarizes olaparib and talazoparib trials showing PFS and quality-of-life benefits for BRCA-associated disease.
Play episode from 01:34
Transcript
